神经病变疼痛市场规模、份额及成长分析（按产品类型、程序、技术、方式、购买类型和地区）－2025-2032 年产业预测

神经病变疼痛市场规模预计在 2023 年达到 26.9 亿美元，并从 2024 年的 28.3 亿美元增长到 2032 年的 42.8 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.3%。

糖尿病等慢性疾病的盛行率不断上升以及人口老化是神经病变疼痛盛行率不断上升的主要因素。这一趋势正在刺激旨在发现创新治疗方法和药物解决方案的重大研发活动，从而推动市场成长。此外，医疗保健专业人员和患者对有效管理神经病变疼痛的认识不断提高，进一步推动了市场扩张。随着製药公司不断推出新药和治疗方法以满足未满足的医疗需求，市场正在蓬勃发展，凸显了创新和不断发展的治疗策略的动态模式。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

神经病变疼痛市场规模（按类型和复合年增长率）（2025-2032）

• 市场概览
• 脊髓刺激（SCS）装置
• 外在周边神经刺激
• 经皮神经电刺激（TENS）装置
• 局部神经病变
• 自主神经病变
• 近端神经病变

神经病变疼痛市场规模（按产品类型和复合年增长率） (2025-2032)

• 市场概览
• 可充电的
• 无法充电

神经病变疼痛市场规模（依治疗类型及复合年增长率） (2025-2032)

• 市场概览
• 侵入性
• 非侵入性

神经病变疼痛市场规模（依技术及复合年增长率） (2025-2032)

• 市场概览
• 经皮电刺激
• 经颅磁刺激
• 呼吸电刺激

神经病变疼痛市场规模（依治疗方式及复合年增长率） (2025-2032)

• 市场概览
• 固定式
• 可携式的

神经病变疼痛市场规模（按购买类型和复合年增长率） (2025-2032)

• 市场概览
• 商用设备
• 处方笺设备

神经病变疼痛市场规模（依疼痛类型和复合年增长率） (2025-2032)

• 市场概览
• 週边神经病变
• 卡压性神经病变
• 幻肢神经症
• 三叉神经痛
• 带状疱疹后遗症神经痛(PHN)
• 神经病变
• 脚痛
• 尾骨疼痛

神经病变疼痛市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概览
• 脊椎狭窄
• 化疗引起的周边神经病变
• 糖尿病神经病变
• 其他的

神经病变疼痛市场规模（按诊断和复合年增长率） (2025-2032)

• 市场概览
• 影像学诊断
• 血液检查
• 身体检查

神经病变疼痛市场规模（依疗法和复合年增长率） (2025-2032)

• 市场概览
• 製药
• 多模态治疗

神经病变疼痛市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 医院
• 诊所
• 家庭医疗保健
• 门诊手术中心
• 研究组织
• 其他的

神经病变疼痛市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概览
• 直接竞标
• 第三方经销商
• 其他的

神经病变疼痛市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Eli Lilly and Company（USA）
• Johnson & Johnson（USA）
• GlaxoSmithKline plc（UK）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Astellas Pharma Inc.（Japan）
• Abbott Laboratories（USA）
• Medtronic plc（Ireland）
• Boston Scientific Corporation（USA）
• Biogen Inc.（USA）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb（USA）
• AbbVie Inc.（USA）
• Grunenthal GmbH（Germany）
• AstraZeneca PLC（UK）
• Daiichi Sankyo Company, Limited（Japan）

结论和建议

Neuropathic Pain Market size was valued at USD 2.69 billion in 2023 and is poised to grow from USD 2.83 billion in 2024 to USD 4.28 billion by 2032, growing at a CAGR of 5.3% during the forecast period (2025-2032).

The rising prevalence of chronic conditions like diabetes and an ageing population are key factors contributing to the increasing incidence of neuropathic pain. This trend is fostering significant research and development activities aimed at discovering innovative therapies and pharmaceutical solutions, which are propelling market growth. Moreover, heightened awareness among healthcare professionals and patients regarding effective neuropathic pain management further fuels this expansion. The market remains vibrant as pharmaceutical companies persistently launch new medications and treatment options to meet the unmet medical needs associated with neuropathic pain, highlighting a dynamic landscape of innovation and evolving therapeutic strategies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Neuropathic Pain market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Neuropathic Pain Market Segments Analysis

Global Neuropathic Pain Market is segmented by Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel and region. Based on Type, the market is segmented into Spinal Cord Stimulation (SCS) Devices, External Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation (TENS) Devices, Focal Neuropathy, Automatic Neuropathy and Proximal Neuropathy. Based on Product Type, the market is segmented into Rechargeable and Non-Rechargeable. Based on Procedure, the market is segmented into Invasive and Non-Invasive. Based on Technology, the market is segmented into Transcutaneous Electrical Nerve Stimulation, Transcranial Magnetic Stimulation and Respiratory Electrical Stimulation. Based on Modality, the market is segmented into Stationary and Portable. Based on Mode of Purchase, the market is segmented into Over-the-Counter Devices and Prescription-Based Devices. Based on Pain Type, the market is segmented into Peripheral Neuropathy, Entrapment Neuropathy, Phantom Limb Neuropathy, Trigeminal Neuralgia, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, Foot Pain and Coccydynia. Based on Indication, the market is segmented into Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy and Others. Based on Diagnosis, the market is segmented into Imaging, Blood Tests and Physical Examination. Based on Treatment, the market is segmented into Medications and Multimodal Therapy. Based on End User, the market is segmented into Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Research Organization and Others. Based on Distribution Channel, the market is segmented into Direct Tender, Third Party Distributor and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Neuropathic Pain Market

The neuropathic pain market is significantly driven by the rising prevalence of chronic illnesses, including diabetes, various types of cancer, and neurological disorders, which has resulted in a greater incidence of neuropathic pain cases worldwide. As the global population ages, the associated risk factors for neuropathic pain are also increasing, further boosting market demand. Additionally, continuous advancements in research and pharmaceutical innovation are leading to the development of new medications and therapies specifically targeting neuropathic pain, thereby improving treatment options. Together, these factors are creating a robust environment for growth in the neuropathic pain market.

Restraints in the Neuropathic Pain Market

A significant constraint in the neuropathic pain market arises from the challenges linked to accurate diagnosis and the inherently subjective nature of pain assessment, which can hinder effective identification and measurement of neuropathic pain. This often results in underreporting or improper management of the condition. Additionally, the high costs associated with sophisticated treatment options and medications may further limit access to these therapies, particularly in regions with constrained healthcare budgets. These factors collectively hinder the growth of the market, affecting both patient outcomes and overall market dynamics in the management of neuropathic pain.

Market Trends of the Neuropathic Pain Market

The neuropathic pain market is witnessing a significant trend towards the development of innovative treatment modalities, driven by a robust focus on research and pharmaceutical advancements. This evolving landscape is catalyzed by the increasing recognition of neuropathic pain's complexities, prompting the exploration of tailored therapeutic solutions. Furthermore, the rise of telehealth and virtual healthcare platforms is transforming the diagnosis, monitoring, and management of neuropathic pain, making care more accessible and personalized. These advancements not only enhance patient engagement but also allow for real-time adjustments to treatment plans, ultimately improving outcomes and driving market growth in this dynamic sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Neuropathic Pain Market Size by Type & CAGR (2025-2032)

• Market Overview
• Spinal Cord Stimulation (SCS) Devices
• External Peripheral Nerve Stimulation
• Transcutaneous Electrical Nerve Stimulation (TENS) Devices
• Focal Neuropathy
• Automatic Neuropathy
• Proximal Neuropathy

Global Neuropathic Pain Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Rechargeable
• Non-Rechargeable

Global Neuropathic Pain Market Size by Procedure & CAGR (2025-2032)

• Market Overview
• Invasive
• Non-Invasive

Global Neuropathic Pain Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Transcutaneous Electrical Nerve Stimulation
• Transcranial Magnetic Stimulation
• Respiratory Electrical Stimulation

Global Neuropathic Pain Market Size by Modality & CAGR (2025-2032)

• Market Overview
• Stationary
• Portable

Global Neuropathic Pain Market Size by Mode of Purchase & CAGR (2025-2032)

• Market Overview
• Over-the-Counter Devices
• Prescription-Based Devices

Global Neuropathic Pain Market Size by Pain Type & CAGR (2025-2032)

• Market Overview
• Peripheral Neuropathy
• Entrapment Neuropathy
• Phantom Limb Neuropathy
• Trigeminal Neuralgia
• Post Herpetic Neuralgia (PHN)
• Post Traumatic Neuropathy
• Foot Pain
• Coccydynia

Global Neuropathic Pain Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Spinal Stenosis
• Chemotherapy-Induced Peripheral Neuropathy
• Diabetic Neuropathy
• Others

Global Neuropathic Pain Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Imaging
• Blood Tests
• Physical Examination

Global Neuropathic Pain Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Medications
• Multimodal Therapy

Global Neuropathic Pain Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Home Healthcare
• Ambulatory Surgical Centers
• Research Organization
• Others

Global Neuropathic Pain Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Direct Tender
• Third Party Distributor
• Others

Global Neuropathic Pain Market Size & CAGR (2025-2032)

• North America (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product Type, Procedure, Technology, Modality, Mode of Purchase, Pain Type, Indication, Diagnosis, Treatment, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grunenthal GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations